5-(1-溴-2-氧代丙基)-2-甲氧基-苯磺酰胺 | 593960-46-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-(1-溴-2-氧代丙基)-2-甲氧基-苯磺酰胺
• 英文名称: 5-(1-bromo-2-oxo-propyl)-2-methoxy-benzenesulfonamide
• 英文别名: 5-(1-Bromo-2-oxopropyl)-2-methoxybenzene-1-sulfonamide；5-(1-bromo-2-oxopropyl)-2-methoxybenzenesulfonamide
• CAS: 593960-46-4
• 化学式: C₁₀H₁₂BrNO₄S
• 分子量: 322.18
• InChiKey: FHZSTHSGBPZHGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  94.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(1-溴-2-氧代丙基)-2-甲氧基-苯磺酰胺 在 ammonium acetate 、 potassium carbonate 、 溶剂黄146 作用下， 以 丙酮 为溶剂， 反应 0.33h， 生成 5-(2-Cyclopropyl-4-methyl-oxazol-5-yl)-2-methoxy-benzenesulfonamide
  参考文献：
  名称：

  2-Alkyloxazoles as potent and selective PI4KIIIβ inhibitors demonstrating inhibition of HCV replication

  摘要：

  Synthesis and SAR of 2-alkyloxazoles as class III phosphatidylinositol-4-kinase beta (PI4KIIIβ) inhibitors is described. These compounds demonstrate that inhibition of PI4KIIIβ leads to potent inhibition of HCV replication as observed in genotype (GT) 1a and 1b replicon and GT2a JFH1 virus assays in vitro.

  DOI：

  10.1016/j.bmcl.2014.07.015
• 作为产物：
  描述：

  2-甲氧基-5-(2-氧代丙基)苯磺酰氯 在 氨 、 三乙胺 、 tribromure de carboxyethyl-2 triphenylphosphonium 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 23.0h， 生成 5-(1-溴-2-氧代丙基)-2-甲氧基-苯磺酰胺
  参考文献：
  名称：

  2-Alkyloxazoles as potent and selective PI4KIIIβ inhibitors demonstrating inhibition of HCV replication

  摘要：

  Synthesis and SAR of 2-alkyloxazoles as class III phosphatidylinositol-4-kinase beta (PI4KIIIβ) inhibitors is described. These compounds demonstrate that inhibition of PI4KIIIβ leads to potent inhibition of HCV replication as observed in genotype (GT) 1a and 1b replicon and GT2a JFH1 virus assays in vitro.

  DOI：

  10.1016/j.bmcl.2014.07.015

文献信息

• [EN] 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS<br/>[FR] DERIVES DU 5-PHENYLTHIAZOL ET LEURS UTILISATIONS COMME INHIBITEURS DE LA PI3 KINASE
  申请人：NOVARTIS AG

  公开号：WO2003072557A1

  公开（公告）日：2003-09-04

  Compounds of Formula I in free or salt form, wherein R1,R2,R3,R4, and R5, have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  式I中的化合物以自由或盐形式存在，其中R1、R2、R3、R4和R5的含义如规范中所示，适用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的过程。
• 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
  申请人：Bruce Ian

  公开号：US20050119320A1

  公开（公告）日：2005-06-02

  Compounds of formula I in free or salt form, wherein R 1 , R 2 , R 3 , R 4 and R 5 have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  式I的化合物，无论是自由形式还是盐形式，其中R1、R2、R3、R4和R5的含义如规范中所示，对于治疗由磷脂酰肌醇3-激酶介导的疾病是有用的。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS
  申请人：Bruce Ian

  公开号：US20100093690A1

  公开（公告）日：2010-04-15

  Compounds of formula I in free or salt form, wherein R 1 , R 2 , R 3 , R 4 and R 5 have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  式I的化合物，无论是自由形式还是盐形式，其中R1、R2、R3、R4和R5的含义如规范中所示，对于治疗由磷脂酰肌醇3-激酶介导的疾病是有用的。还描述了含有这些化合物的制药组合物以及制备这些化合物的过程。
• 5-phenylthiazole derivatives and use as PI3 kinase inhibitors
  申请人：Novartis AG

  公开号：US08129541B2

  公开（公告）日：2012-03-06

  Compounds of formula I in free or salt form, wherein R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  公式I的化合物，无论是自由形式还是盐形式，其中R1、R2、R3、R4和R5的含义如规范中所示，可用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了包含这些化合物的制药组合物和制备这些化合物的过程。
• 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors
  申请人：Novartis AG

  公开号：US07687637B2

  公开（公告）日：2010-03-30

  Compounds of formula I in free or salt form, wherein R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  公式I的化合物，无论是自由形式还是盐形式，其中R1、R2、R3、R4和R5的含义如规范中所示，可用于治疗由磷脂酰肌醇3-激酶介导的疾病。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。